Document Type


Publication Date



This article has been peer reviewed. It is the authors' final version prior to publication in Virology journal

2006 Aug 29;3:60.

The published version is available at DOI: 10.1186/1743-422X-3-60. Copyright © BioMedCentral


Enormous effort has been devoted to the development of a vaccine against human immunodeficiency virus (HIV). But it is proving to be an unprecedented challenge to create an effective vaccine mainly due to the high genetic variability of the virus and the necessity of cytotoxic T lymphocytes (CTL) for containing the infection. Currently pursued vaccine strategies appear to induce CTL in nonhuman primate models but in the early clinical trials, these strategies fail to fully control the viral infection. New strategies that can cover the vast genetic diversity of HIV are needed for the development of a potent vaccine.